Showing 1731-1740 of 10612 results for "".
Skincare for Skin Health: Counseling the Aesthetic Patient
https://reachmd.com/ma-supplements/2022-mar-apr-insert2/skincare-for-skin-health-counseling-the-aesthetic-patient/35159/Aesthetic physicians say being involved in patients’ decisions about everyday skincare regimens can boost skin quality and reinforce the aesthetic provider’s expertiseComprehensive Biomarker Testing in mBC Informs Clinical Decision Making
https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.PI3K Pathway Inhibitors: Safety and Tolerability Profiles
https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/Compare TROP2-targeted ADCs for mBC by molecular structure, patient eligibility, and clinical evidence to guide patient-centered treatment strategiesTriple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Understanding Endocrine Resistance in HR+/HER2- mBC
https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Diagnostic Challenges in Refractory Chronic Cough: From Burden to Solutions
https://reachmd.com/programs/cme/diagnostic-challenges-in-refractory-chronic-cough-from-burden-to-solutions/50973/Part of the educational program Bridging Specialties®: Timely Diagnosis and Treatment for Refractory Chronic Cough, this activity examines the diagnostic challenges associated with refractory chronic cough (RCC) and the importance of coordinated, guideline-directed evaluation across specialties. RCC